Patents by Inventor Christoph Spiess

Christoph Spiess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250032610
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Application
    Filed: June 24, 2024
    Publication date: January 30, 2025
    Applicant: Genentech, Inc.
    Inventors: Paul CARTER, Christoph SPIESS, Yiyuan YIN, Jianhui ZHOU, Wendy SANDOVAL, Jacob CORN, Michael DILLON
  • Publication number: 20250011471
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: March 15, 2024
    Publication date: January 9, 2025
    Applicant: GENENTCH, INC
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Publication number: 20240383984
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Application
    Filed: May 28, 2024
    Publication date: November 21, 2024
    Inventors: Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle Dicara, Diego Ellerman, Christoph Spiess, Paul J. Carter
  • Publication number: 20240360229
    Abstract: The present invention provides anti-C-C motif chemokine receptor 8 (CCR8) antigen-binding molecules (e.g., bispecific antigen-binding molecules) and compositions thereof. The invention also features polynucleotides, vectors, host cells, methods of production, pharmaceutical compositions, methods of treating a disease or disorder, such as cancer, methods of depleting regulatory T cells, related uses and compositions for use, and kits for use with the one or more methods.
    Type: Application
    Filed: January 18, 2024
    Publication date: October 31, 2024
    Inventors: Christoph SPIESS, Baomei WANG, Ambrose Jon WILLIAMS, Cecilia Pui Chi CHIU, Michael Andrew DILLON, Teemu Tapani JUNTTILA, James Thomas KOERBER
  • Patent number: 12053525
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: August 6, 2024
    Assignee: Genentech, Inc.
    Inventors: Paul Carter, Christoph Spiess, Yiyuan Yin, Jianhui Zhou, Wendy Sandoval, Jacob Corn, Michael Dillon
  • Patent number: 12030947
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: July 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle Dicara, Diego Ellerman, Christoph Spiess, Paul J. Carter
  • Publication number: 20240190966
    Abstract: Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same.
    Type: Application
    Filed: November 7, 2023
    Publication date: June 13, 2024
    Inventors: WeiYu LIN, Christoph SPIESS, Liping SUN, Yan WU, Cecilia P.C. CHIU, Walter Christian DARBONNE, Michael Andrew DILLON
  • Publication number: 20240092906
    Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Inventors: Diego ELLERMAN, Teemu T. Junttila, Twyla Noelle Lombana, Dionysos Slaga, Christoph Spiess
  • Publication number: 20240026033
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: March 31, 2023
    Publication date: January 25, 2024
    Applicant: Genentech, Inc.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Patent number: 11866498
    Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Diego Ellerman, Teemu T. Junttila, Twyla Noelle Lombana, Dionysos Slaga, Christoph Spiess
  • Patent number: 11845799
    Abstract: Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 19, 2023
    Assignee: Genentech, Inc.
    Inventors: WeiYu Lin, Christoph Spiess, Liping Sun, Yan Wu, Cecilia P. C. Chiu, Walter Christian Darbonne, Michael Andrew Dillon
  • Publication number: 20230357445
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Justin SCHEER, Christoph SPIESS, Daniel G. YANSURA
  • Patent number: 11555076
    Abstract: The invention provides anti-MIC antibodies and methods of using the same.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 17, 2023
    Assignee: Genentech, Inc.
    Inventors: Twyla Noelle Lombana, Christoph Spiess, Jeong Kim, Evangeline Toy, Jill Schartner, Zhengmao Ye, Jack Bevers, III, Ryan Cook, Marissa Matsumoto, Amy Berkley
  • Publication number: 20220409725
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 29, 2022
    Applicant: Genentech, Inc.
    Inventors: Paul CARTER, Christoph SPIESS, Yiyuan YIN, Jianhui ZHOU, Wendy SANDOVAL, Jacob CORN, Michael DILLON
  • Patent number: 11434482
    Abstract: The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. The invention also provides methods of identifying binding polypeptides with improved expression. The invention also provides engineered bacteria suitable for use in the methods of the invention. The invention also provides compositions that can be obtained using the methods, for example, anti-interleukin-13 (IL-13) antibodies with improved expression and/or stability. The invention also provides libraries comprising binding polypeptide (e.g., antibody) variants.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Twyla Noelle Lombana, Rebekah McKenna, Christoph Spiess, Karthik Veeravalli, Michael Dillon
  • Publication number: 20220064331
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: June 8, 2021
    Publication date: March 3, 2022
    Applicant: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Publication number: 20220048990
    Abstract: The presently disclosed subject matter provides antibodies, e.g., IgA antibodies and IgG-IgA fusion molecules, and compositions comprising such antibodies, as well as methods of making and using such antibodies and compositions.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 17, 2022
    Applicant: GENENTECH, INC.
    Inventors: Twyla Noelle Lombana, Julie A. Zorn, Marissa L. Matsumoto, Christoph Spiess, Claudio Ciferri, Alberto Estevez
  • Publication number: 20220048993
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Inventors: Isidro HOTZEL, Teemu T. JUNTTILA, Ji LI, Justin SCHEER, Danielle DICARA, Diego ELLERMAN, Christoph SPIESS, Paul J. CARTER
  • Patent number: 11192950
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: December 7, 2021
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle Dicara, Diego Ellerman, Christoph Spiess, Paul J. Carter
  • Patent number: 11116840
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 14, 2021
    Assignee: Genentech, Inc.
    Inventors: Paul Carter, Christoph Spiess, Yiyuan Yin, Jianhui Zhou, Wendy Sandoval, Jacob Corn, Michael Dillon